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Risk of other Cancers in Families 
with Melanoma: Novel Familial 
Links
Christoph Frank1, Jan Sundquist2,3, Akseli Hemminki4,5 & Kari Hemminki1,2
A family history of cutaneous melanoma (‘melanoma’) is a well-established risk factor for melanoma. 
However, less is known about the possible familial associations of melanoma with other discordant 
cancers. A risk for discordant cancer may provide useful information about shared genetic and 
environmental risk factors and it may be relevant background data in clinical genetic counseling. Using 
the Swedish Family-Cancer Database, we assessed the relative risk (RR) for any cancer in families with 
increasing numbers of first-degree relatives diagnosed with melanoma, including multiple melanoma, 
and in reverse order RR for melanoma in families of multiple discordant cancers. Close to 9% of 
melanoma was familial; among these 92% were in 2-case families and 8% in families with 3 cases or 
more. Cancers that were associated with melanoma, in at least two independent analyses, included 
breast, prostate, colorectal, skin and nervous system cancers. Other associations included cancer 
of unknown primary, acute myeloid leukemia/myelofibrosis and Waldenström macroglobulinemia/
myeloma. Significant results, which appear biologically plausible, were also obtained for rare nasal 
melanoma and mesothelioma. Although small samples sizes and multiple comparisons were of concern, 
many of the above associations were internally consistent and provide new diverse leads for discordant 
familial association of melanoma.
According to the Swedish Family-Cancer Database family history of cutaneous melanoma was found for 5 to 10% 
of first-degree relatives (FDRs) diagnosed with this cancer, giving a familial relative risk (RR) of 2.51. However, 
less is known about the possible familial associations of cutaneous melanoma (subsequently ‘melanoma’ if not 
specified) with other discordant cancers. In a systematic analysis of familial risks, between discordant sites, the 
highest relative risk for melanoma (1.35) was found in families of skin squamous cell carcinoma (SCC) patients. 
Weak associations were also found with colorectal, breast and nervous system cancers2. In a study from Utah, 
which covered three generations, two-way associations were found between melanoma and breast, female genital, 
lip and prostate cancers3. Multiple cancers in the same individual are a hallmark of a familial risk, and indeed we 
have found that the familial risk for melanoma was equal for persons who have 2 relatives diagnosed with a single 
melanoma or 1 relative with 2 primary melanomas4. Several discordant familial cancers, particularly pancreatic 
and breast cancers, were noted in persons with multiple primary melanomas5. The most common high-risk gene 
predisposing to melanoma is CDKN2A, which is also associated with pancreatic cancer6. Germline mutations in 
BAP1 also predispose to cutaneous melanoma, but the mutations are relatively more important in rare cancers 
(uveal melanoma and mesothelioma) constituting a novel cancer syndrome6–8. Although a few other high pene-
trance genes are known for cutaneous melanoma their population impact is negligible because of the low number 
of mutation carriers.
A risk for discordant cancer may provide useful information about shared genetic and environmental risk 
factors and it may be relevant background data in clinical genetic counseling. In the case of melanoma, it would 
be pertinent to assess familial clusters, with sites which are manifested in CDKN2A and BAP1 mutation carriers, 
or whether the risks could be extended to as yet unknown cancer sites. In this study we have applied a novel 
approach to search for familial associations of melanoma with other cancers using the most recent update of 
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the Swedish Family-Cancer Database. This involves assessment of familial RRs for melanoma in families with 
increasing numbers of cancers X, or conversely, familial RR for cancer X in families with increasing numbers of 
melanomas. We additionally consider the joint occurrence of multiple primary melanomas among familial cases. 
Association with rare non-cutaneous melanomas was also tested.
Results
The total number of melanomas was 79,060 and of these a total of 38,102 (including 28,495 invasive melanomas) 
were in the 0–80 year offspring generation for which the RRs were calculated. The case distribution by the number 
of FDRs diagnosed with melanoma is shown in Table 1. Only 8.57% of melanoma patients had a family history 
of melanoma. Among 3,267 melanoma patients with a family history, 3,007 (92.0% of melanoma with a family 
history) had one affected family member (2-case families), 239 (7.3%) had two affected family members (3-case 
families) and 21 (0.6%) had three or more affected family members (multiplex families). RRs for melanoma 
increased systematically from 2.42 (2-case families) to 6.49 and 8.30 (4 or more cases with melanoma).
The RR for any cancer in offspring was calculated when increasing numbers of FDRs were diagnosed with 
single or multiple melanomas (Table 2). The reference was families with no melanoma in FDRs; the RR in the 
reference families was 1.00 (not shown) and the corresponding number of cases with a negative family history 
of melanoma is shown in the first results column. If one family member had melanoma, increased RRs were 
detected for nasal (1.64; 4.89 for nasal melanoma), prostate (1.08), testicular (1.17), kidney (1.17), skin (1.46), 
nervous system (1.27) and thyroid gland cancers (1.28) as well as for non-Hodgkin lymphoma (1.12) and CUP 
of melanoma histology (2.23). If there was one FDR with multiple melanomas, significantly increased RRs for 
discordant associations were found for cancers of the small intestine (2.34, 3.01 for small intestinal NET), lung 
(1.64), breast (1.25), skin (2.00) and bone (2.60; 4.10 for osteosarcoma). Discordant cancer cases with 2 or more 
affected FDRs were rare. However, significantly increased risks were observed for salivary gland (3.21), colorectal 
(2.77), pancreatic (4.46), nasal (6.35; 21.67 for nasal melanoma), breast (1.61), cervix (2.85), prostate (1.71), skin 
(2.62/2.32 depending on numbers of melanomas in the family) and eye cancers (3.06; 4.15 for eye melanoma), and 
non-Hodgkin lymphoma (3.07), myeloma (5.02) and leukemia (1.77). A significant increasing trend, for RRs by 
the number of melanomas among FDR, was confirmed for colorectal, nasal, lung, breast, prostate, testicular, kid-
ney, skin, eye, nervous system and thyroid cancers, and for non-Hodgkin lymphoma and leukemia considering 
95% CIs.
In order to test the association with non-cutaneous melanomas in sites not listed in Table 2, no associations 
were noted for esophageal or female genital melanomas but the case numbers were few (data not shown). We 
similarly tested for association with NET for sites other than small intestine (stomach, appendix, rectum, nose, 
ovary, kidney and CUP); no associations were noted but case numbers were few (data not shown).
In view of the recently described BAP1 associated cancer syndrome manifesting melanomas and mesothelio-
mas, we tested the risk of mesothelioma when cutaneous melanomas were diagnosed in FDRs. The RR was 1.55 
for combined pleural and peritoneal mesothelioma (N = 51, 95% CI 1.12–2.15) when one FDR was diagnosed 
with melanoma and it was 2.14 (2, 0.43–10.75) when 2 FDRs were diagnosed with melanoma. The trend test was 
significant (p = 0.009). Neither pleural nor peritoneal mesothelioma were independently significant, but most 
cases (36) originated from pleural mesothelioma.
We also carried out the analysis in the reverse order (conversely), calculating RRs for melanoma when FDRs 
were diagnosed with any cancer (Table 3). However, as a few cancers showed multiple affected relatives only two 
family history categories were used (one familial cancer or two or more patients with the same familial cancer), 
in addition to the reference category lacking familial cancers. Significantly increased RRs were found if one FDR 
had nasal melanoma (2.24), or breast (1.06), prostate (1.05), skin (1.36), eye (1.35, 1.33 for eye melanoma), nerv-
ous system cancer (1.17) or CUP of melanoma histology (2.09). Individuals with 2 or more familial skin cancers 
showed a significant RR for melanoma of 1.78. Testing for increasing trends for RRs by the number of familial 
cases showed associations with colorectal, breast, prostate, skin and nervous system cancer. We separately ana-
lyzed families with 3 or more patients diagnosed with the same cancer. The RR for melanoma was significant 
(1.62; 27 cases, 95% CI 1.03–2.53), only for families in which 3 men were diagnosed with prostate cancer.
Based on some positive results for non-Hodgkin lymphoma and leukemia in Table 2, a more detailed analysis 
was conducted by considering subtypes (Table 4). RR was increased for follicular lymphoma (6.75) when at least 
2 family members were diagnosed with melanoma and when at least one family member was diagnosed with 
multiple melanomas. With the same family history Waldenström macroglobulinemia increased to 15.45 (one 
case) but it was also increased (5.27) when one family member was diagnosed with multiple melanoma. Among 
leukemias, the risk was systematically increased for acute myeloid leukemia, reaching an RR of 7.08 in the most 
affected melanoma families (Table 4). Rare myelofibrosis was increased to 5.55, when 2 or more family members 
Affected relatives Frequency RR 95% CI % in melanoma (% familial melanoma)
0 34835 1.00 — 91.43 (− )
1 3007 2.42 2.30–2.54 7.89 (92.0)
2 239 6.49 5.44–7.76 0.63 (7.3)
3 21 8.30 6.65–10.01 0.06 (0.6)
Table 1.  Distribution of melanoma cases by the number of melanoma patients in family members and 
relative riska. aOnly patients with first invasive or in situ melanoma were considered.
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were diagnosed with melanoma. The analyses shown in Table 4 were also carried in reverse order but no RR was 
significant (data not shown).
Discussion
The interpretation of any familial risk needs to weigh the evidence about known contributing genes and envi-
ronmental factors. Data on twin or family-based heritability estimates do not provide much guidance because 
familial melanoma covers less than 10% of all melanoma9. Ultraviolet radiation is a known risk factor for mela-
noma and the modest correlation of melanoma risk between spouses (1.22) was suggested to be due, at least in 
part, to shared sun exposure among spouses10. The high shared risks between melanoma and skin squamous cell 
carcinoma shown here may be due to ultraviolet radiation, but for other cancers genetic sharing may be more 
important.
As to the genetic architecture of melanoma, high-risk CDKN2A mutations contribute to about 30% of mel-
anomas in families of three or more affected individuals11. According to a recent Swedish study, CDKN2A pos-
itive families accounted for 11.5% (31/269) of all families, and these presented with a median of 6 melanomas 
compared to 2 in mutation negative families12. We show here that families of 3 or more diagnosed melanomas 
accounted for less than 8% of familial melanoma, which together with the above data suggest that CDKN2A 
mutations are likely to be, at most, a minor contributor to the present findings on discordant cancers. The case of 
pancreatic cancers in melanoma families is instructive in this context because CDKN2A is the dominant high-risk 
gene for both cancers11. The only significant RR for pancreatic cancer was the high risk of 4.46 in families with at 
least 2 melanomas and one with multiple melanomas; however, such families included no more than 2% (5 of 222) 
of the pancreatic cancer patients with a family history of melanoma.
Cancer site
Cases negative 
family history
1 FDR had melanoma
1 FDR had multiple (≥2) 
melanomas ≥2 FDRs had melanoma
≥2 FDRs had melanoma,≥1 
FDR had multiple melanomas
P-trend test 
for RR
Cases RR 95% CI Cases RR 95% CI Cases RR 95% CI Cases RR 95% CI p-value
Upper aerodigestive tract 8416 252 0.92 (0.74–1.14) 22 1.33 (0.65–2.72) 5 0.67 (0.15–2.99) 2 2.58 (0.10–12.23) 0.60
Salivary glands 1091 36 1.01 (0.72–1.41) 3 1.37 (0.44–4.29) 3 3.21 (1.02–10.07) 0 0.31
Stomach 5244 160 0.99 (0.81–1.21) 6 0.65 (0.24–1.79) 9 2.09 (0.92–4.78) 0 0.73
Small intestine 1757 55 0.96 (0.74–1.24) 8 2.34 (1.19–4.59) 1 0.64 (0.10–4.31) 0 0.61
 NET 850 30 1.08 (0.74–1.57) 5 3.01 (1.21–7.50) 1 1.33 (0.17–10.20) 0
Colorectum 34098 1137 1.05 (0.98–1.13) 70 1.10 (0.84–1.44) 36 1.23 (0.84–1.79) 19 2.63 (1.61–4.60) 0.0052
Liver 5692 184 1.09 (0.93–1.27) 10 1.04 (0.53–2.04) 4 0.91 (0.31–2.61) 3 2.68 (0.83–9.88) 0.22
Pancreas 6369 201 1.05 (0.84–1.30) 8 0.75 (0.26–2.18) 8 1.58 (0.54–4.61) 5 4.32 (1.11–17.11) 0.49
Nose 554 29 1.64 (1.09–2.45) 2 1.87 (0.42–8.43) 3 6.35 (1.86–21.70) 0 0.0015
 Nasal melanoma 51 8 4.89 (2.13–11.20) 0 1 21.67 (2.40–195) 0 0.0002
Lung 23546 731 1.02 (0.94–1.11) 67 1.64 (1.25–2.16) 24 1.25 (0.79–1.97) 9 2.03 (0.97–4.34) 0.0138
Breast 80034 2861 1.04 (1.00–1.08) 215 1.25 (1.08–1.45) 126 1.61 (1.33–1.96) 18 0.99 (0.58–1.61) <0.0001
Cervix 8621 306 1.06 (0.93–1.20) 13 0.71 (0.38–1.32) 5 0.67 (0.25–1.80) 5 2.75 (1.02–7.68) 0.70
Endometrium 10877 348 0.99 (0.82–1.20) 18 0.86 (0.38–1.95) 5 0.52 (0.11–2.44) 6 2.30 (0.53–9.83) 0.84
Ovary 9595 339 1.07 (0.96–1.19) 26 1.35 (0.93–1.96) 8 0.94 (0.48–1.84) 2 0.91 (0.20–3.76) 0.12
Prostate 59570 2074 1.08 (1.03–1.13) 132 1.17 (0.99–1.40) 66 1.21 (0.94–1.54) 22 1.71 (1.11–2.64) <0.0001
Testis 7222 266 1.17 (1.01–1.35) 14 0.94 (0.50–1.75) 9 1.68 (0.77–3.65) 2 1.60 (0.30–8.65) 0.0314
Kidney 9088 325 1.17 (1.04–1.31) 16 0.97 (0.58–1.63) 11 1.48 (0.80–2.77) 0 0.0127
Urinary bladder 13432 443 1.04 (0.94–1.16) 33 1.32 (0.91–1.92) 12 1.02 (0.55–1.91) 5 1.63 (0.61–4.63) 0.14
Skin, squamous cell 23648 1130 1.46 (1.37–1.56) 94 2.00 (1.60–2.50) 57 2.62 (1.97–3.49) 13 2.39 (1.29–4.38) <0.0001
Eye 1779 66 1.26 (0.98–1.61) 4 1.24 (0.47–3.30) 4 3.06 (1.15–8.13) 0 0.0197
 Eye melanoma 828 31 1.14 (0.83–1.57) 3 1.83 (0.67–4.97) 3 4.15 (1.53–11.29) 0 0.0357
Nervous system 21364 827 1.27 (1.16–1.39) 51 1.27 (0.89–1.80) 23 1.39 (0.82–2.36) 5 1.31 (0.40–4.09) <0.0001
Thyroid gland 5344 224 1.28 (1.10–1.48) 10 0.91 (0.46–1.81) 3 0.67 (0.19–2.33) 1 9.07 (1.31–37) 0.0454
Endocrine glands 9302 328 1.07 (0.93–1.23) 22 1.17 (0.69–1.98) 12 1.47 (0.72–3.01) 5 3.04 (0.83–7.92) 0.14
Bone 1833 64 1.17 (0.85–1.62) 9 2.60 (1.11–6.09) 1 0.78 (0.06–9.95) 1 3.44 (0.24–40) 0.06
 Osteosarcoma 676 21 1.10 (0.71–1.70) 5 4.10 (1.70–9.92) 0 0 0.12
Connective tissue 3633 129 1.15 (0.93–1.41) 7 1.01 (0.42–2.42) 1 0.35 (0.04–3.54) 0 0.41
Non-Hodgkin lymphoma 13803 485 1.12 (1.02–1.23) 32 1.22 (0.85–1.75) 13 1.13 (0.64–1.98) 8 2.88 (1.32–6.19) 0.0021
Hodgkin lymphoma 4277 145 1.10 (0.88–1.38) 13 1.54 (0.74–3.23) 2 0.64 (0.10–4.16) 0 0.26
Myeloma 3940 130 1.02 (0.85–1.24) 10 1.33 (0.68–2.62) 3 0.86 (0.25–2.96) 4 4.77 (1.65–14.51) 0.21
Leukemia 14141 439 1.08 (0.96–1.20) 32 1.29 (0.86–1.94) 18 1.77 (1.03–3.04) 4 1.64 (0.52–5.41) 0.0169
CUP 8827 311 1.17 (0.96–1.43) 23 1.54 (0.75–3.16) 10 1.45 (0.49–4.33) 0 0.06
 CUP melanoma 683 50 2.23 (1.45–3.44) 4 2.98 (0.68–13.03) 1 1.68 (0.09–31.84) 0 0.0004
Table 2.  Risk of cancer in families with increasing numbers of melanoma patients and multiple melanomas.
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Genome-wide association studies have been able to identify 20 genome-wide significant low-risk loci. Overall, 
these loci are estimated to account for 19.2% of the familial risk of melanoma13. Of the 20 loci, 8 were skin specific, 
including 5 related to pigmentation and 3 related to nevi, and an additional 4 were in regions related to telomere 
maintenance13. Considering the genetic architecture, it is conceivable that the weight of the high-risk genes can 
be observed in families with multiple melanoma patients, while the low-risk genes contribute predominantly to 
the small melanoma families. However, as many of the low-risk genes are skin specific they may not be relevant in 
discordant associations, except with skin cancer.
A number of novel observations emerged in this new type of analysis for cancer risk considering family his-
tories of increasing numbers of affected family members. The focus was on discordant cancers, but for family 
histories only the same discordant cancers were considered. Being an exploratory study we have to be concerned 
about multiple comparisons. There are a limited number of earlier independent studies on the related questions 
and all are much smaller than the present one; thus comparison to the previous literature will provide limited 
reassurance. Biological plausibility and internal consistency need to be assessed. For the latter, the results are ana-
lyzed in two ways (risk of cancer by family history of melanoma, Table 2, and risk of melanoma by family history 
of cancer, Table 3) are largely independent (see Methods) and increased risk for both analyses should indicate a 
strong support for a true association. However, the two-way analysis compares cancers of different age distribu-
tions, which may reduce comparability of the two sets of results. Thus, a lack of two-way support is not strong 
evidence against association. A key consistency metric for true association is the trend test for RRs in families 
with increasing numbers of affected family members, allowing a ‘dose-response’ type of analysis. With a sufficient 
sample size the dose-response relationship should be consistent.
Considering internal consistency of data, i.e. evidence of dose-response or significant results on two-way anal-
ysis, skin cancer indisputably shares risk with melanoma, with ultraviolet radiation being the common risk factor 
Cancer site family member
Cases negative 
family history
1 discordant case ≥2 discordant casesa Trend test for RR
Cases RR 95% CI Cases RR 95% CI p-value
Upper aerodigestive tract 37529 568 0.96 (0.87–1.06) 5 0.96 (0.35–2.63) 0.40
Salivary glands 38022 80 1.23 (0.92–1.63) 0
Stomach 37189 904 0.95 (0.88–1.03) 9 0.71 (0.32–1.56) 0.15
Small intestine 37964 137 1.14 (0.94–1.39) 1 2.05 (0.20–21.05) 0.18
 NET 38032 70 1.10 (0.81–1.49) 0
Colorectum 34967 2980 1.05 (1.00–1.11) 155 1.24 (0.99–1.56) 0.0150
Liver 37452 643 0.95 (0.86–1.05) 7 1.15 (0.44–3.04) 0.38
Pancreas 37435 661 0.96 (0.87–1.06) 6 0.83 (0.29–2.32) 0.33
Nose 38060 42 0.93 (0.58–1.49) 0
 Nasal melanoma 38090 12 2.64 (1.23–5.68) 0
Lung 36201 1834 0.97 (0.92–1.04) 67 1.08 (0.79–1.48) 0.56
Breast 34249 3660 1.06 (1.02–1.10) 193 1.10 (0.93–1.31) 0.0028
Cervix 37644 456 0.91 (0.81–1.01) 2 0.78 (0.15–4.04) 0.07
Endometrium 37354 744 1.00 (0.92–1.08) 4 0.53 (0.18–1.57) 0.75
Ovary 37445 650 1.07 (0.98–1.17) 7 1.31 (0.56–3.04) 0.13
Prostate 33840 4029 1.05 (1.01–1.10) 233 1.09 (0.93–1.28) 0.0081
Testis 37987 114 1.10 (0.88–1.37) 1 1.54 (0.14–16.64) 0.40
Kidney 37277 815 1.07 (0.98–1.16) 10 1.33 (0.62–2.86) 0.12
Urinary bladder 36833 1245 1.00 (0.93–1.08) 24 1.12 (0.67–1.88) 0.84
Skin, squamous cell 35298 2681 1.36 (1.30–1.43) 123 1.78 (1.42–2.22) <0.0001
Eye 37992 109 1.35 (1.05–1.74) 1 6.65 (0.48–91.93) 0.0543
 Eye melanoma 38019 83 1.33 (1.01–1.74) 0
Nervous system 37138 949 1.17 (1.08–1.26) 15 1.40 (0.78–2.51) <0.0001
Thyroid gland 37863 238 1.09 (0.93–1.27) 1 0.74 (0.07–8.07) 0.32
Endocrine glands 37580 515 1.10 (0.99–1.22) 7 1.72 (0.70–4.22) 0.07
Bone 38061 41 0.87 (0.60–1.26) 0
 Osteosarcoma 38096 6 0.56 (0.18–1.75) 0
Connective tissue 37892 210 1.19 (0.97–1.47) 0
Non-Hodgkin lymphoma 37246 851 1.04 (0.95–1.14) 5 0.50 (0.15–1.61) 0.60
Hodgkin lymphoma 37977 125 0.96 (0.77–1.21) 0
Myeloma 37700 399 1.05 (0.93–1.19) 3 1.18 (0.28–4.98) 0.45
Leukemia 37281 810 1.08 (0.98–1.18) 11 1.21 (0.56–2.66) 0.10
CUP 37214 882 1.04 (0.96–1.13) 6 0.76 (0.29–1.97) 0.41
 CUP melanoma 38042 60 2.09 (1.44–3.05) 0
Table 3.  Risk of melanoma in families of increasing numbers of patients with discordant concordant 
cancers. aFamily members had the same discordant cancers, e.g., 2 or more lung cancers.
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while no shared contributing genes are known. Breast and prostate cancers were associated in many independent 
analyses with melanoma. The risk of colorectal cancer was 2.77 in multiplex melanoma families and both of the 
two-way trend analyses were significant. Nervous system and thyroid cancers also showed independent support 
for being true associations, both may also manifest CDKN2A mutations or deletions6.
Among hematologic neoplasms, associations were shown with melanoma and Waldenström macroglobu-
linemia, acute myeloid leukemia and myelofibrosis. Although the case numbers were small and warrant caution, 
there was internal consistency. Waldenström macroglobulinemia is a plasma cell disease related to myeloma and 
shows mutual familial risks14; myeloma risk was 5.02 in the most familial melanoma families, supporting the 
results of Waldenström macroglobulinemia (Table 2). Myelofibrosis is known to be able to progress to acute and 
chronic myeloid leukemia thus giving basis to the increased risk found in Table 415.
It is known that ocular and cutaneous melanomas share familial risks and BAP1 and possibly also BRCA2 
mutations may be involved6–8. However, melanomas are found, although rarely, in other locations including nasal 
and anogenital mucosal surfaces and the esophagus but whether they cluster with cutaneous melanoma has not 
been shown. Here we show that nasal melanoma was associated with cutaneous melanoma in the two-way anal-
yses, but there was no indication for esophageal or female genital melanomas due to inconclusive data because 
of low case numbers. A two-way association was shown for CUP with melanoma histology. CUP is a fatal cancer 
where the primary tumor cannot be found and the diagnosis is based on metastases16. We have shown earlier 
familial clustering of a number of primary cancers with CUP, speculating that the associated primary cancer in 
the family member may point to the hidden primary in CUP17,18. The present results concur and suggest that 
CUP is maintaining the histology of a family member’s melanoma. We showed an association between cutaneous 
melanoma and mesothelioma, which could be expected as a manifestation of the novel BAP1-associated cancer 
syndrome, and would provide population-level evidence for the syndromic clustering of these cancers6–8.
The increased risk in small intestinal cancers prompted us to consider histology of the associated tumors and it 
was found that NETs contributed to the risk. Although the association with melanoma was surprising, the embry-
onic origin of these tumors may be the common denominator. Melanocytes arise in the neural crest and migrate 
to skin, while the neuroendocrine cells that give rise to NET are also thought to originate from this embryonic 
tissue19. However, no associations were found for NETs at other tested sites but with small case numbers.
In summary, the applied novel approach identified many cancers that were associated with melanoma, at least 
in two independent analyses but with few known genetic links. Breast and prostate cancers were reliably asso-
ciated with melanoma but also colorectal and nervous system cancers as well as CUP, acute myeloid leukemia/
myelofibrosis and Waldenström macroglobulinemia/myeloma showed fair statistical support for true associations 
but for which genetic bases remain unknown. Associations of melanoma with nasal melanoma and mesothelioma 
appear biologically plausible but more intriguing was the association with small intestinal NET. Although small 
samples sizes and multiple comparisons were of concern, many of the above associations were internally con-
sistent and provide new diverse leads and incentives for genetic search beyond the present narrowly demarcated 
familial domain of melanoma, encompassing essentially only skin and pancreatic cancers.
Methods
In the Swedish Family-Cancer Database 15.7 million individuals are categorized in families with cancer data 
from the Swedish Cancer Registry. All cancers since 1958 are registered and the latest follow-up of the database 
includes cancers up to and including 2012. The offspring generation is constituted of all individuals born from 
1932 onwards, with parental linkage, and includes 8.5 million people; among which 427,196 cancers were diag-
nosed. They had reached the maximum age of 80, while the ages of their biological parents (the parental genera-
tion) were not limited.
Cancer site
Cases 
negative 
family 
history
1 FDR had melanoma
1 FDR had multiple (≥2) 
melanomas ≥2 FDRs had melanoma
≥2 FDRs had melanoma, ≥1 
FDR had multiple melanomas Trend test for RR
Cases RR 95% CI Cases RR 95% CI Cases RR 95% CI Cases RR 95% CI p-value
Diffuse large cell 2911 93 1.02 (0.82–1.26) 8 1.47 (0.72–2.99) 1 0.41 (0.06–3.09) 0 0.84
Follicular 2148 74 1.03 (0.80–1.33) 3 0.69 (0.20–2.38) 4 2.07 (0.71–6.04) 3 6.75 (1.96–23.25) 0.16
Waldenström 294 8 0.83 (0.42–1.64) 3 5.27 (1.75–15.91) 1 3.65 (0.54–24.55) 1 15.45 (2.30–104) 0.11
Hairy cell 335 16 1.39 (0.79–2.44) 0 1 3.16 (0.35–28.48) 0 0.17
Acute lymphoid 
leukemia 3257 73 1.08 (0.87–1.33) 7 1.68 (0.84–3.34) 1 0.83 (0.13–5.15) 0 0.29
Chronic lymphoid 
leukemia 3075 116 1.17 (0.97–1.42) 7 1.21 (0.57–2.56) 2 0.73 (0.18–3.01) 1 1.63 (0.22–11.92) 0.16
Acute myeloid 
leukemia 2548 75 0.99 (0.75–1.30) 13 2.85 (1.48–5.48) 6 3.19 (1.22–8.35) 3 7.08 (1.81–27.61) 0.0239
Chronic myeloid 
leukemia 1273 37 0.90 (0.61–1.31) 3 1.17 (0.31–4.38) 2 1.88 (0.37–9.50) 0 0.96
Polycythemia vera 1075 45 1.26 (0.97–1.65) 0 1 1.02 (0.18–5.87) 0 0.13
Myelofibrosis 829 27 1.01 (0.68–1.52) 1 0.62 (0.08–4.91) 4 5.55 (1.97–15.59) 0 0.18
Table 4.  Risk for specific subtypes of non-Hodgkin lymphoma and leukemia in families with increasing 
number of melanoma patients and multiple melanomas.
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Using the 7th revision of the International Classification of Diseases (ICD-7) the 34 most common can-
cers were used in the analysis; data are not shown for 4 very rare cancers. Histological type since the 1960s was 
recorded by pathological-anatomical coding. For only non-Hodgkin lymphomas histological type was recorded 
by SNOMED-coding (Systematized Nomenclature of Medicine) available from 1993. For melanoma both invasive 
and in situ diagnoses were considered. Multiple melanomas were considered only in patients who had invasive 
or in situ melanoma. The follow-up for cancer in offspring started from the beginning of 1958, the birth year, or 
the immigration year, whichever came latest. The follow-up was terminated when a person was diagnosed with 
cancer, emigrated or died, or at the end of 2012, whichever came first.
Methods of calculating familial relative risks (RRs) for individuals whose FDRs (parents and/or siblings) were 
diagnosed with cancer have been described elsewhere1. Incidence rates for persons with affected relatives were 
compared to rates for those whose relatives had no relevant cancer. Incidence rates were obtained by counting 
cases and person-years (PY) according to family history of discordant cancer:
RR for cancer X, given family history of melanoma: (X cases with family history of melanoma divided by PY 
for X with family history of melanoma) divided by (X cases without family history of melanoma divided by PY for 
X without family history of melanoma).
According to the converse analysis:
RR for melanoma, given family history of X: (Melanoma cases with family history of X divided by PY for 
melanoma with family history of X) divided by (melanoma cases without family history of X divided by PY for 
melanoma without family history of X).
Note that none of the terms are identical in these two-way analyses, implying that for offspring-parent pairs 
the results are independent but for siblings the pairs of cases are the same.
RRs were stratified for sex, age group, calendar period, residential area and socioeconomic status to account 
for potential confounders. These variables were used as covariates in a Poisson regression model to get adjusted 
RRs and corresponding confidence intervals (CIs). Trend tests were performed by modeling the number of famil-
ial cancers as a continuous covariate.
Ethical statement. The study was approved by the Ethical Committee of Lund University and the study was 
conducted in accordance with the approved guidelines.
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